Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
62.97
+3.13 (5.23%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Rhythm Pharmaceuticals Employees
Rhythm Pharmaceuticals had 283 employees as of December 31, 2024. The number of employees increased by 57 or 25.22% compared to the previous year.
Employees
283
Change (1Y)
57
Growth (1Y)
25.22%
Revenue / Employee
$459,809
Profits / Employee
-$934,883
Market Cap
3.98B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
RYTM News
- 1 day ago - Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025 - GlobeNewsWire
- 16 days ago - Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder - Seeking Alpha
- 17 days ago - Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial - Reuters
- 17 days ago - Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity - GlobeNewsWire
- 18 days ago - Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity - GlobeNewsWire
- 5 weeks ago - Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd. - GlobeNewsWire
- 5 weeks ago - Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan - GlobeNewsWire
- 5 weeks ago - Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration - GlobeNewsWire